1. European Medicines Agency. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products CHMP/SWP/28367/07 (EMA, London; 2007). <
http://www.ema.europa.eu/pdfs/human/swp/2836707enfin.pdf
>
2. US Food and Drug Administration (FDA). Guidance for Industry and Reviewers, Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers (FDA, Washington, DC; 2002). <
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf
>
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline E8: General Considerations for Clinical Trials. (ICH, Geneva; 1997). <
http://www.ich.org/LOB/media/MEDIA484.pdf
>
4. European Medicines Agency (EMA). Note for Pre-clinical Pharmacological and Toxicological Testing of Vaccines CPMP/SWP/465/95. (EMA, London; 1997). <
http://www.ema.europa.eu/pdfs/human/swp/046595en.pdf
>
5. European Medicines Agency (EMA). Guideline on Clinical Evaluation of New Vaccines CHMP/VWP/164653/05. (EMA, London; 2006). <
http://www.ema.europa.eu/pdfs/human/vwp/16465305enfin.pdf
>